Boston Trust Walden Corp Lowers Holdings in Medtronic PLC $MDT

Key Points

• Boston Trust Walden Corp cut its stake in Medtronic by 58.6% in Q4, selling 30,478 shares and leaving 21,576 shares valued at about $2.07 million.
• Medtronic slightly beat quarterly expectations with $1.36 EPS vs. $1.34 and $9.02B revenue (up 5.8% YoY), set FY2026 guidance of 5.620–5.660 EPS, and pays a $0.71 quarterly dividend (3.4% yield).
• Sentiment is mixed: several analysts have trimmed price targets though the consensus is a "Moderate Buy" with an average target of $107.80; an EVP sold 52,524 shares and institutions own about 82% of the stock.

Boston Trust Walden Corp decreased its stake in Medtronic PLC (NYSE:MDT - Free Report) by 58.6% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 21,576 shares of the medical technology company's stock after selling 30,478 shares during the quarter. Boston Trust Walden Corp's holdings in Medtronic were worth $2,073,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of the stock. State Street Corp boosted its stake in shares of Medtronic by 1.0% in the third quarter. State Street Corp now owns 60,460,537 shares of the medical technology company's stock worth $5,800,550,000 after buying an additional 625,992 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Medtronic by 0.9% in the third quarter. Bank of New York Mellon Corp now owns 21,468,260 shares of the medical technology company's stock worth $2,044,637,000 after buying an additional 192,410 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its stake in shares of Medtronic by 0.5% in the third quarter. Massachusetts Financial Services Co. MA now owns 21,086,499 shares of the medical technology company's stock worth $2,008,278,000 after buying an additional 98,220 shares during the last quarter. Raymond James Financial Inc. boosted its stake in shares of Medtronic by 3.0% in the third quarter. Raymond James Financial Inc. now owns 11,203,865 shares of the medical technology company's stock worth $1,067,055,000 after buying an additional 327,899 shares during the last quarter. Finally, Wellington Management Group LLP boosted its stake in shares of Medtronic by 35.3% in the third quarter. Wellington Management Group LLP now owns 10,189,586 shares of the medical technology company's stock worth $970,456,000 after buying an additional 2,658,981 shares during the last quarter. Hedge funds and other institutional investors own 82.06% of the company's stock.

Medtronic Stock Up 0.7%

Shares of MDT opened at $83.80 on Friday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.87 and a current ratio of 2.54. Medtronic PLC has a one year low of $79.93 and a one year high of $106.33. The stock has a market capitalization of $107.59 billion, a price-to-earnings ratio of 23.34, a PEG ratio of 2.16 and a beta of 0.75. The stock has a 50 day moving average price of $90.10 and a 200 day moving average price of $95.36.

Medtronic (NYSE:MDT - Get Free Report) last announced its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.34 by $0.02. The company had revenue of $9.02 billion for the quarter, compared to analysts' expectations of $8.89 billion. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The firm's quarterly revenue was up 5.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.38 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities research analysts forecast that Medtronic PLC will post 5.57 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, April 17th. Stockholders of record on Friday, March 27th were issued a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a dividend yield of 3.4%. The ex-dividend date was Friday, March 27th. Medtronic's payout ratio is currently 79.11%.

Key Stories Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Completed CathWorks deal and new investment broaden Medtronic’s AI heart-care footprint (adds AI coronary diagnostics; also led a $100M investment in Pulnovo) — accelerates higher-margin, software-enabled offerings that can lift long-term growth. Read More.
• Positive Sentiment: Commercial progress: first surgeons have used the Stealth AXiS Autopilot surgical robotic platform — marks a tangible commercialization milestone for Medtronic’s robotics strategy and could support procedure volume and recurring revenue. Read More.
• Positive Sentiment: Investor interest in strategic moves — coverage noting a new GE HealthCare tie-up and Altaviva launch alongside M&A/launch activity has drawn attention to potential catalysts for re-rating if momentum continues. Read More.
• Neutral Sentiment: Analyst stance: Jefferies reiterated a Hold and says portfolio streamlining (including the diabetes spin-off) has benefits but is offset by a lower growth outlook and valuation compression — supports cautious investor positioning. Read More.
• Neutral Sentiment: UBS trimmed its price target to $90 from $104 and maintains a neutral rating — near-term analyst-driven cap on upside until execution or guidance surprises. Read More.
• Neutral Sentiment: Industry tailwinds: multiple market reports name Medtronic as a leading player in catheters, home/long-term care devices, and automated insulin-delivery systems — underscores TAM exposure but not immediate earnings impact. Read More.
• Neutral Sentiment: Corporate recognition: Medtronic’s CISO was honored at the HoustonCISO ORBIE Awards — positive PR but limited direct stock impact. Read More.
• Negative Sentiment: Share weakness and volatility: recent coverage highlights a notable YTD decline and short-term selloffs, which can pressure multiples and invite further analyst scrutiny if momentum doesn’t recover. Read More.
• Negative Sentiment: Recent daily dip: headlines note a larger-than-market intraday move downward in recent sessions — reinforcing near-term investor caution. Read More.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. UBS Group lowered their target price on Medtronic from $104.00 to $90.00 and set a "neutral" rating on the stock in a research note on Wednesday. Stifel Nicolaus reduced their price target on Medtronic from $105.00 to $95.00 and set a "hold" rating for the company in a report on Monday, April 6th. Argus reduced their price target on Medtronic from $125.00 to $115.00 and set a "buy" rating for the company in a report on Monday, April 6th. Piper Sandler reduced their price target on Medtronic from $105.00 to $91.00 and set a "neutral" rating for the company in a report on Wednesday, April 1st. Finally, Weiss Ratings cut Medtronic from a "buy (b-)" rating to a "hold (c+)" rating in a report on Tuesday. Fifteen research analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $107.80.

Insider Transactions at Medtronic

In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of the company's stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $97.71, for a total value of $5,132,120.04. Following the completion of the sale, the executive vice president directly owned 32,768 shares in the company, valued at $3,201,761.28. This represents a 61.58% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.26% of the stock is currently owned by insiders.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic's offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).

Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.